의약품에서의 성별차이 및 유발요인

키워드

참고문헌 (117)

1. "Protecting and Advancing Women’s Health: The FDA Office of Women’s Health Progress Report 10 years and Beyond"[URL]
2. "Gender-based Analysis"[URL]
3. "Health Canada's Gender-based Analysis Policy"[URL]
4. Mojaverian P, "Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time", Clin Pharmacol Ther, 41, pp.11~17 (1987)
5. Frezza M, "High blood alcohol levels in women. The role of decreased gastric alcoholdehydrogenase activity and first-pass etabolism", N Engl J Med, 322, pp.95~99 (1990)
6. Ochs HR, "Diazepam kinetics in relation to age and sex", Pharmacology, 23, pp.24~30 (1981)
7. Greenblatt DJ, "Diazepam disposition determinants", Clin Pharmacol Ther, 27, pp.301~312 (1980)
8. Kristjánsson F, "Disposition of alprazolam in human volunteers. Differences between genders", Acta Pharm Nord, 3, pp.249~250 (1991)
9. Wedel M, "Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers", Alcohol, 26, pp.329~336 (1991)
10. Succari M, "Microheterogeneity of α1-acid glycoprotein: variation during the menstrual cycle in healthy women, and profile in women receiving estrogen-progestogen treatment", Clin Chim Acta, 187, pp.235~241 (1990)
11. Tuck CH, "Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women", Arterioscler Thromb Vasc Biol, 17, pp.1822~1829 (1997)
12. Brinkman-Van der Linden CM, "Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals", Arterioscler Thromb Vasc Biol, 6, pp.407~12 (1996)
13. Cummins CL, "Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein", Clin Pharmacol Ther, 72, pp.474~489 (2002)
14. Kahan BD, "Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay", Transplantation, 41, pp.459~464 (1986)
15. Austin KL, "Intersubject and dose related variability after intravenous administration of erythromycin", Br J Clin Pharmacol, 10, pp.273~279 (1980)
16. Dilger K, "Chronopharmacology of intravenous and oral modified release verapamil", Br J Clin Pharmacol, 47, pp.413~419 (1999)
17. Krecic-Shepard ME, "Race and sex influence clearance of nifedipine: results of a population study", Clin Pharmacol Ther, 68, pp.130~142 (2000)
18. Lemmens HJ, "Influence of age on the pharmacokinetics of alfentanil. Gender dependence", Clin Pharmacokinet, 19, pp.416~422 (1990)
19. Wenk M, "Effect of St. John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, Nacetyltransferase 2, and xanthine oxidase in healthy males and females", Br J Clin Pharmacol, 57, pp.495~499 (2004)
20. Lamba V, "CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression", J Pharmacol Exp Ther, 307, pp.906~922 (2003)
21. Gross JL, "Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA", Braz J Med Biol Res, 25, pp.129~134 (1992)
22. Rathore SS, "Sex-based differences in the effect of digoxin for the treatment of heart failure", N Engl J Med, 347, pp.1403~1411 (2002)
23. Ducharme MP, "Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight", Ther Drug Monit, 16, pp.513~518 (1994)
24. Frame BC, "Population pharmacokinetics of continuous infusion ceftazidime", Clin pharmacokinet, 37, pp.343~350 (1999)
25. Barbhaiya RH, "Effects of age and gender on pharmacokinetics of cefepime", Antimicrob Agents Chemother, 36, pp.1181~1185 (1992)
26. Reigner BG, "Factors influencing elimination and distribution of fleroxacin: meta analysis of individual data from 10 pharmacokinetic studies", Antimicrob Agents Chemother, 40, pp.575~80 (1996)
27. Wong LT, "Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects", Br J Clin Pharmacol, 39, pp.81~84 (1995)
28. Gaudry SE, "Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine", Clin Pharmacol Ther, 54, pp.23~27 (1993)
29. Legato M, "Gender and the heart: sex-specific differences in normal anatomy and physiology", J Gend Specif Med, 3, pp.15~18 (2000)
30. Burke JH, "Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect", Am J Med, 100, pp.537~543 (1996)
31. Liu K, "Ethnic differences in blood pressure, pulse rate, and related characteristics in young adults. The CARDIA study", Hypertension, 14, pp.218~226 (1989)
32. Bazett HC, "An analysis of the time-relations of electrocardiograms", Heart, 7, pp.353~370 (1920)
33. Villareal RP, "Gender and cardiac arrhythmias", Tex Heart Inst J, 28, pp.265~275 (2001)
34. Schwartz JB, "The influence of sex on pharmacokinetics", Clin Pharmacokinet, 42, pp.107~121 (2003)
35. Hogstedt S, "Increased oral clearance of metoprolol in pregnancy", Eur J Clin Pharmacol, 24, pp.217~220 (1983)
36. Llerena A, "Interethnic differences in drug metabolism: influence of genetic and environmental factors on desrisoquine hydroxylation phenotype", Eur J Drug Metabol Pharmacokinet, 21, pp.129~138 (1996)
37. Wadelius M, "Induction of CYP2D6 in pregnancy", Clin Pharmacol Ther, 62, pp.400~407 (1997)
38. Kam KW, "Estrogen reduces cardiac injury and expression of beta1-adrenoceptor upon ischemic insult in the rat heart", Pharmacol Exp Ther, 309, pp.8~15 (2004)
39. Thawornkaiwong A, "Upregulation of b1-adrenergic receptors in ovariectomized rat hearts", Life Sci, 72, pp.1813~1824 (2003)
40. Labbe’ L, "Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates", Pharmacogenetics, 10, pp.425~438 (2000)
41. Luzier AB, "Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers", Clin Pharmacol Ther, 66, pp.594~601 (1999)
42. Kendall MJ, "Metoprolol pharmacokinetics and the oral contraceptive pill", Br J Clin Pharmacol, 14, pp.120~122 (1982)
43. Walle T, "Propranolol metabolism in normal subjects: association with steroid hormones", Clin Pharmacol Ther, 56, pp.127~132 (1994)
44. Gilmore DA, "Age and gender influence the stereoselective pharmacokinetics of propranolol", J Pharmacol Exp Ther, 261, pp.1181~1186 (1992)
45. Walle T, "Biologic determinants of propranolol disposition: results from 1308 patients in the beta-Blocker Heart Attack Trial", Clin Pharmacol Ther, 38, pp.509~518 (1985)
46. Massana E, "No sex-related pharmacokinetic and pharmacodynamic differences of captopril", Pharmacol Res, 36, pp.41~47 (1997)
47. Pfeffer MA, "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial", N Engl J Med, 327, pp.669~677 (1992)
48. Kimmelstiel C, "Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes", Cardiology, 77, pp.71~79 (1990)
49. Vree TB, "Lack of male–emale differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose", Scientific World J, 3, pp.1332~1343 (2003)
50. Rathore SS, "Association of serum digoxin concentration and outcomes in patients with heart failure", JAMA, 289, pp.871~878 (2003)
51. Blaustein MP, "Sex, digitalis, and the sodium pump", Mol Interv, 3, pp.68~72 (2003)
52. Smith JB, "Influence of race, sex, and blood pressure on erythrocyte sodium transport in humans", Hypertension, 12, pp.251~258 (1988)
53. Green HJ, "Normal skeletal muscle Na(þ)-K(þ) pump concentration in patients with chronic heart failure", Muscle Nerve, 24, pp.69~76 (2001)
54. Rathore SS, "Association of serum digoxin concentration and outcomes in patients with heart failure", JAMA, 289, pp.871~878 (2003)
55. Rathore SS, "Sex-based differences in the effect of digoxin for the treatment of heart failure", N Engl J Med, 347, pp.1403~1411 (2002)
56. Nicoline Jochmann, "Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases", Eur Heart J, 26, pp.1585~1585 (2005)
57. Israili ZH, "Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension", J Hum Hypertens, 14, pp.73~86 (2000)
58. Krecic-Shepard ME, "Race and sex influence clearance of nifedipine: results of a population study", Clin Pharmacol Ther, 68, pp.130~142 (2000)
59. Kloner RA, "for the Amlodipine Cardiovascular Community Trial Study Group. Sex- and age-related antihypertensive effects of amlodipine", Am J Cardiol, 77, pp.713~722 (1996)
60. Isaacsohn J, "Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults", Eur J Clin Pharmacol, 56, pp.897~903 (2001)
61. Shepard DR, "Gender, hyperlipidemia, and coronary artery disease", Compr Ther, 29, pp.7~17 (2003)
62. Avram MJ, "Determinants of Thiopental Induction Dose Requirements", Anesth Analg, 76, pp.10~7 (1993)
63. Vuyk J, "Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion", Br J Anaesth, 86, pp.183~188 (2001)
64. Høymork S.C, "Bispectral index, predicted and measured drug levels of targetcontrolled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence", Acta Anaesthesiologica Scandinavica, 44, pp.1138~1144 (2000)
65. De Kock M, "Postoperative P.C.A. in abdominal surgery. Analysis of 200 consecutive patients", Acta anaesthesiologica Belgica, 42, pp.85~91 (1991)
66. Sarton E, "Sex Differences in Morphine Analgesia : An Experimental Study in Healthy Volunteers", Anesthesiology, 93, pp.1245~1254 (2000)
67. "Burns J, Hodsman N, McLintock T, et al., The influence of patient characteristics on the requirements for postoperative analgesia", Anaesthesia, 44, pp.2~6 (1989)
68. Sidebotham D, "The Safety and Utilization of Patient-Controlled Analgesia", J Pain Symptom Manage, 14, pp.202~209 (1997)
69. Tsui SL, "The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients", Anaesth Intensive Care, 24, pp.658~664 (1996)
70. Pleym H, "Gender differences in drug effects: implications for anesthesiologists", Acta Anaesthesiologica Scandinavica, 47, pp.241~259 (2003)
71. Gourlay G.K, "Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain", Anesth Analg, 67, pp.329~337 (1988)
72. Gear R.W, "Kappaopioids produce significantly greater analgesia in women than in men", Nature Medicine, 2, pp.1248~1250 (1996)
73. Gear R.W, "Gender difference in analgesic response to the kappa-opioid pentazocine", Neurosci Lett, 205, pp.207~209 (1996)
74. Gear R.W, "The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain", Pain, 83, pp.339~345 (1999)
75. Wing L.M, "Lidocaine disposition-Sex differences and effects of cimetidine", Clin Pharmacol Ther, 35, pp.695~701 (1984)
76. Xue F.S, "The pharmacokinetics of vecuronium in male and female patients", Anesth Analg, 86, pp.1322~1327 (1998)
77. Parker C.J, "Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium", Br J Anaesth, 69, pp.439~443 (1992)
78. Xue F.S, "Dose-response curve and time-course of effect of vecuronium in male and female patients", Br J Anaesth, 80, pp.720~724 (1998)
79. Besch CL, "Antiretroviral therapy in drug-naive patients infected with human immunodeficiency virus", Am J Med Sci, 328, pp.3~9 (2004)
80. Ofotokun I, "Antiretroviral pharmacokinetic profile: A review of sex differences", Gend Med, 4(2), pp.106~119 (2007)
81. Rebecca Clark, "Sex differences in antiretroviral therapyassociated intolerance and adverse events", Drug Saf, 28, pp.1075~1083 (2005)
82. Floridia M, "Gender differences in the treatment of HIV infection", Pharmacol Res, 58, pp.173~182 (2008)
83. Anderson PL, "Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals", AIDS, 17, pp.2159~2168 (2003)
84. Stretcher BN, "Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus", Antimicrob Agents Chemother, 38, pp.1541~1547 (1999)
85. de Maat MM, "Population pharmacokinetics of nevirapine in an unselected cohort of HIV-l-infected individuals", Br J Clin Pharmacol, 54, pp.378~385 (2002)
86. Hitti J, "For the adult AIDS Clinical Trial Group Study 398. Sex and weight as covariates in the pharmacokinetics of efavirenz, indinavir, and nelfinavir", Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (2004)
87. Fletcher CV, "Sex based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 3S9", lnfect Dis, 189, pp.1176~1184 (2004)
88. Pai MP, "Sex related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1", Pharmacotherapy, 24, pp.592~599 (2004)
89. Trout H, "Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and", or wasting syndrome, 2004, pp.48, 538~545
90. "Roche Laboratories Inc. and Trimeris Inc"[URL]
91. Finkel DG, "Women have a greater immunological response to effective virological HIV-1 therapy", AIDS, 17 (2003)
92. Giordano TP, "Do sex and race", ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy?, 2003, pp.37, 433~437
93. Moore AL, "Gender differences in virologic response to treatment in an HIV-positive population: a cohort study", J Acquir Immune Defic Syndr, 26, pp.159~163 (2001)
94. Turner BJ, "Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users", J Gen Intern Med, 18, pp.248~257 (2003)
95. Murri R, "Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study", J Acquir Immune Defic Syndr, 34, pp.184~190 (2003)
96. Moore AL, "Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited", J Acquir Immune Defic Syndr, 32, pp.452~461 (2003)
97. Lichenstien K, "Clinical factors associated with incidence and prevalence of fat atrophy and accumulation", Antivir Ther, 5, pp.61~62 (2000)
98. Muurahainen N, "Gender differences in lipodystrophy syndrome evaluated by SALSA", 3rd International Conference on Nutrition in HIV Infection (1999)
99. Nguyen ML, "Use of HAART in women: similar response but greater toxicity", 14th International AIDS Conference (2002)
100. "Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV infected men and women"[URL]
101. "Fat redistribution in HIV patients on non-protease (PI) Regimens–Study in 6 Centers in Nigeria"[URL]
102. McDermott AY, "Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women", Am J Clin Nutr, 74, pp.679~686 (2001)
103. Ofotokun I, "Sex differences in adverse reactions to antiretroviral drugs", Topics in HIV medicine, 11(2), pp.55~59 (2003), the International AIDS Society
104. Moore RD, "Adverse events from drug therapy for human immunodeficiency virus disease", Am J Med, 101, pp.34~40 (1996)
105. Boxwell DE, "Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors", 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (1999)
106. Mazhude C, "Ethnic and gender differences in non-nucleoside reverse transcriptase inhibitor (NNRTI) induces rash", 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (2001)
107. Bersoff-Matcha SJ, "Sex difference in nevirapine rash", Clin Infect Dis, 32, pp.124~129 (2001)
108. Sanne I, "Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor", AIDS, 14(Suppl 4), pp.S12~ (2000)
109. Currier JS, "Gender differences in adverse events on ritonavir. An analysis from Abbott 247", 1st National Conference on Women and HIV (1997)
110. Harris RZ, "Gender effects in pharmacokinetics and pharmacodynamics", Drugs, 50, pp.222~239 (1995)
111. Ofotokun I, "Sex differences in the pharmacological effects of antiretroviral drugs: potential roles of drug transporters and Phase 1 and 2 metabolizing enzymes", Topics in HIV medicine : a publication of the International AIDS Society, 12(2), pp.79~83 (2005), the International AIDS Society
112. Schuetz EG, "Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms", J Pharmacol Exp Ther, 275, pp.1011~1018 (1995)
113. Steiner H, "Differences in rhodamine- 123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity", Ann Hematol, 76, pp.189~194 (1998)
114. "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services"[URL]
115. Baylor MS, "Hepatotoxicity associated with nevirapine use", J Acquir Immune Defic Syndr, 35(5), pp.538~539 (2004)
116. Lactic Acidosis International Study Group, "Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy", AIDS, 21(18), pp.2455~2464 (2007)
117. Nicastri E, "Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review", J Antimicrob Chemother, 60, pp.724~732 (2007)

관련 논문AI추천